BrosMed Enters USA Coronary Angioplasty Catheter Market

BrosMed Enters USA Coronary Angioplasty Catheter Market

August 1st, 2015, BrosMed announced that BrosMed Medical and US Endovascular Enter into Exclusive Agreement to Distribute Coronary Angioplasty Catheters into USA Market.

Following the 510(k) clearance of both Artimes and Apollo balloon dilatation catheter, BrosMed made long-term exclusive distribution agreement with US Endovascular for its PTCA pipeline for the United States of America market.

“Brosmed management has a long history in the international marketplace and is proud of its quality and production system as we ready for a US market launch. We expect that this long-term agreement with USE will benefit both our strategies” -Benny Lee, CEO of Brosmed Medical Co., Ltd.

Artimes and Apollo PTCA Technology Highlights:

Apollo is a truly non-compliant high pressure post-dilatation catheter, which offers numerous features: folded balloon for crossibility, flexibility and exceptional balloon rewrap; spiral extrusion catheter; low crossing profile for enhanced robust and non-compliant balloon. Extraordinary minor (3.0%) axial growth and 5F guiding catheter compatible. Balloon sizes 2.0-5.0mm and lengths 8-18mm. Average burst pressure (ABP) is 30atm.

Artimes is a semi-compliant pre-dilation catheter offering numerous features: folded balloon for crossibility, flexibility and exceptional balloon rewrap, spiral extrusion catheter; low crossing profile to facilitate the physician and procedure. Balloon sizes are designed for tight lesions and treatment of CTOs.

“We are extremely excited about the agreement we have with US Endovascular. BrosMed Medical was looking for a distribution partner in the United States with the same philosophy about how to adapt to the changes in this market.”

“Like USE, BrosMed Medical is a very fast growing entrepreneurial company with offices in China, The Netherlands and India, supporting distributors and physicians globally.”

“This is a significant step forward for BrosMed to increase global sales, and to seek US FDA approval for additional coronary and peripheral endovascular devices that will include advanced technology.”- Jos De Korte, VP Sales and Marketing and GM of Brosmed Medical BV Netherlands.

About BrosMed Medical

BrosMed Medical is more than just a company; we are leading the medical device design and manufacturing revolution.

BrosMed Medical develops, manufactures and markets medical devices primarily used by interventional cardiologists, radiologists and vascular surgeons in angioplasty procedures and other minimal invasive devices.

We provide solutions to our customers through innovative design, effective supply chain management, world-class manufacturing, and flexible channels of distribution and through the development or acquisition of innovative technologies.

About US Endovascular (USE)

US Endovascular (USE) is engaged in the procurement, licensing & distribution of medical device products used in peripheral endovascular and coronary procedures. The fundamental premise is to obtain next-generation, clinically-relevant products from manufacturers and market directly to the end user/ economic buyer. This approach eliminates all unnecessary layers, significantly reducing cost.

USE product portfolio includes: next-generation peripheral arterial laser technology (pending FDA 510k approval); next-generation PTA and PTCA balloon technology; peripheral guide wires. These product segments are used in greater than 95% of peripheral and endovascular and coronary procedures.

In 2015, the estimated size of the US market is 3.4M coronary procedures: 2.1M diagnostic and 1.2M intervention. On average, 2.1 angioplasty balloons (PTCA) are used per procedure for a total market opportunity of 2.5M units. Until today, the US PTCA market has consisted of only three medical device companies: Medtronic; Abbott Vascular; Boston Scientific. US Endovascular now makes it four, entering the PTCA market with the goal of fundamentally changing the narrative.